ycanth
Generic: cantharidin·Code: VP-102
ycanth: developed by 1 company · 1 FDA decision.
ycanth evidence translation
What we can confirm
1 FDA record
What it means
Source-backed records connect ycanth to VRCA; that link alone does not prove the drug works.
What to watch
Watch for new trials or company disclosures after the FDA record.
BioSniper AIPage evidence connected
Prepared research question
How could ycanth → VRCA affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
common warts
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Verrica Pharmaceuticals Inc. (VRCA) common warts | Phase 3 |
FDA Decisions1 records
Approval1 INDICATIONS AND USAGE YCANTH is indicated for the topical treatment of molluscum contagiosum in adult and pediatric patients 2 years of age and older. YCANTH is indicated for the topical treatment of molluscum contagiosum in adult and pediatric patients 2 years of age and older. ( 1 )(VRCA)FDA ↗
NDA212905Type 5 - New Formulation or New ManufacturerStandardTopicalSolution
Frequently asked questions
Who is developing ycanth?
ycanth is being developed by Verrica Pharmaceuticals Inc..
What is ycanth's latest FDA decision?
The most recent tracked FDA decision for ycanth is Approval for 1 INDICATIONS AND USAGE YCANTH is indicated for the topical treatment of molluscum contagiosum in adult and pediatric patients 2 years of age and older. YCANTH is indicated for the topical treatment of molluscum contagiosum in adult and pediatric patients 2 years of age and older. ( 1 ), dated July 21, 2023.